#Pfizer
-
BioNTech posts tripled Q1 vaccine sales but still flags full-year decline
-
Georgia gets first batch of Covid-19 pills Paxlovid
-
Pfizer to provide 10 mln courses of COVID pill to developing countries -the Global Fund
-
US Pfizer's Azerbaijani office announces its liquidation
-
Pfizer jabs for children aged 5-12 to arrive in Georgia in Q2
-
China grants conditional approval for Pfizer's oral COVID-19 drug
-
Pfizer's COVID cash pile opens opportunities for deals
-
Israel signs deal with Novavax for COVID vaccine
-
EMA conditionally approves Pfizer's COVID-19 pill
-
Pfizer, BioNTech start clinical trial of Omicron-specific COVID-19 vaccine
-
Azerbaijan to get another batch of Sputnik V vaccine against COVID-19 in 2022
-
Pfizer and BioNTech launch trial of Omicron-targeted COVID vaccine
-
EU regulator set to rule on Pfizer COVID pill by end-Jan, ahead of Merck
-
Pfizer, Moderna boosters up to 90% effective against Omicron: CDC
-
Pfizer CEO sees annual COVID vaccine rather than frequent boosters
-
Japan approves Pfizer's COVID-19 vaccine for children aged 5-11
-
4th Pfizer, Moderna shot less effective against Omicron: Israeli study
-
Pfizer says it applied for Japan gov't approval for oral COVID-19 drug
-
Pfizer to cut U.S. sales staff as meetings with healthcare providers move to virtual
-
U.S. reports 1.35 mln COVID-19 cases in a day, shattering global record
-
Britain approves Pfizer's antiviral COVID-19 pill
-
S.Korea authorises emergency use of Pfizer's oral coronavirus treatment
-
AstraZeneca vaccine booster works against Omicron, Oxford lab study finds
-
Pfizer pill becomes first US-authorized home COVID-19 treatment
